SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)

SpyGlass Pharma 收购参天制药株式会社（Santen）旗下子公司 AVS 的全部已发行股份，AVS 是 SpyGlass Pharma 人工晶状体（IOL）的现有制造商。

Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL System

为其第三阶段领先候选产品BIM-IOL系统确保可扩展的商业化人工晶状体（IOL）生产能力

Accelerates pathway to adding premium lens options into its IOL-based drug delivery system

加速将高端镜片选项整合到其基于人工晶状体的药物递送系统中的进程

SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies

SpyGlass Pharma 打算继续支持使用其专有 IOL 材料技术的 AVS 客户和被许可方，例如参天制药、博士伦以及其他全球 IOL 公司。

IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash.

加利福尼亚州尔湾，2026年10月1日（环球社讯）——SpyGlass Pharma, Inc.（纳斯达克股票代码：SGP）（“SpyGlass Pharma”或“公司”）今日宣布，以约1300万美元现金收购眼科医疗器械公司、人工晶状体（IOL）及晶状体材料制造商Advanced Vision Science, Inc.（AVS）的全部已发行普通股。

This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System..

此次收购为SpyGlass Pharma确保了可扩展的商业化人工晶状体（IOL）生产能力。AVS曾是参天制药株式会社（Santen）的全资子公司，目前是SpyGlass Pharma在两项评估BIM-IOL系统的III期注册临床试验中的人工晶状体供应商。

Under the agreement, AVS will be the exclusive manufacturer and supplier of several types of IOLs to Santen for commercialization in Japan. Additionally, AVS will continue to license its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for use in the enVista® IOL line, and manufacture products for other global IOL companies..

根据协议，AVS将成为向参天制药独家生产和供应多种类型人工晶状体（IOL）的制造商和供应商，用于在日本市场商业化。此外，AVS将继续向博士伦授权其无闪光疏水性丙烯酸镜片材料，用于enVista®人工晶状体系列，并为其他全球人工晶状体公司生产产品。

“The acquisition of AVS for SpyGlass Pharma is strategically important as it secures our long-term supply of world class IOLs,” said Patrick Mooney, CEO of SpyGlass Pharma. “Not only are we owning significant manufacturing capability of approved IOL material, trusted and widely adopted by surgeons worldwide, but we are also positioning ourselves to accelerate production of a portfolio of lenses that we believe can fit our drug delivery pads.

“SpyGlass Pharma 收购 AVS 具有战略重要性，因为它确保了我们长期获得世界一流的晶状体（IOL）供应，”SpyGlass Pharma 首席执行官 Patrick Mooney 表示。“我们不仅拥有了经批准的 IOL 材料的重要生产能力，该材料深受全球外科医生的信任并广泛采用，而且我们还 positioning 自己以加速生产一系列我们认为可以适配我们的药物递送垫的镜片。”

While our monofocal IOL addresses the vast majority of the glaucoma and ocular hypertension patients with cataracts, some of these patients can benefit from premium IOL options like toric and extended depth-of-focus lenses. This is a major step toward delivering on these aspirations, while maintaining our strategy, focus and existing cash runway.”.

虽然我们的单焦点人工晶状体能够满足绝大多数伴有白内障的青光眼和高眼压症患者的需求，但部分患者亦可从散光矫正型及延长景深型等高端人工晶状体选项中获益。这是在保持公司战略、专注方向及现有现金跑道不变的前提下，向实现这些愿景迈出的重要一步。

“AVS has built a strong reputation for innovation, quality, and manufacturing excellence,” said Rie Nakajima, Director of the Board, Chief Operating Officer of Santen Global. “We believe SpyGlass Pharma is well positioned to leverage these strengths to maximize the value of innovative products and further advance efforts to address unmet needs in eye care around the world.”.

“AVS 在创新、质量和卓越制造方面建立了良好的声誉，”参天全球董事兼首席运营官中岛理惠表示。“我们相信，SpyGlass Pharma 能够充分利用这些优势，最大化创新产品的价值，并进一步推动满足全球眼科护理领域未竟需求的工作。”

Gitkin & Co. serves as financial advisor to SpyGlass Pharma. Wilson Sonsini Goodrich & Rosati, P.C., serves as legal counsel to SpyGlass Pharma.

Gitkin & Co. 担任 SpyGlass Pharma 的财务顾问。Wilson Sonsini Goodrich & Rosati, P.C. 担任 SpyGlass Pharma 的法律顾问。

MTS Health Partners, L.P., serves as financial advisor to Santen and Squire Patton Boggs (US) LLP serves as legal counsel to Santen.

MTS Health Partners, L.P. 担任参天制药的财务顾问，而 Squire Patton Boggs (US) LLP 则担任参天制药的法律顾问。

About Advanced Vision Science, Inc.

关于先进视觉科学公司

Advanced Vision Science, Inc. (AVS) is a California-based medical device company specializing in the research, development and manufacturing of ophthalmic medical devices including intraocular lenses and lens material. The Advanced Vision Science Foldable Hydrophobic Acrylic IOL was the first foldable hydrophobic acrylic lens proven to be glistening free.

Advanced Vision Science, Inc.（AVS）是一家总部位于加利福尼亚州的医疗器械公司，专注于眼科医疗器械（包括人工晶状体及晶状体材料）的研发与生产。Advanced Vision Science 可折叠疏水性丙烯酸酯人工晶状体是首款被证实无闪辉现象的可折叠疏水性丙烯酸酯晶状体。

The lens was launched in Japan in July 2008 and is marketed by Santen under the brand name “Eternity” ®..

该镜片于2008年7月在日本推出，由参天制药以“Eternity”®品牌进行销售。

The hydrophobic acrylic lens material and line-extensions are licensed to and marketed in the rest of world by Bausch + Lomb Inc. (B+L).

疏水性丙烯酸镜片材料及线延伸产品由博士伦公司（Bausch + Lomb Inc.，简称B+L）获得授权，并在世界其他地区进行市场推广。

AVS has been manufacturing ophthalmic devices since 1975. The AVS quality system is certified to ISO 13485. The facility is registered by the US FDA and Japanese Ministry of Health, Labour and Welfare.

AVS 自1975年以来一直从事眼科设备的制造。AVS的质量体系已通过ISO 13485认证。该设施已在美国食品药品监督管理局（FDA）以及日本厚生劳动省注册。

About the Bimatoprost Drug Pad-IOL System

关于比马前列素药物垫-人工晶状体系统

SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

SpyGlass Pharma 的主要候选产品为比马前列素药垫-人工晶状体系统（BIM-IOL 系统），该系统由附着在其人工晶状体上的新型专有非生物可降解药垫组成，旨在常规白内障手术期间植入，以降低患有开角型青光眼（OAG）或高眼压症（OHT）患者的眼内压（IOP）升高。

The BIM-IOL System is designed to consistently deliver three years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT..

BIM-IOL 系统旨在持续三年递送比马前列素，这是一种前列腺素类似物，于 2001 年获得美国食品药品监督管理局（FDA）批准用于局部给药，以降低开角型青光眼（OAG）或高眼压症（OHT）患者的眼内压（IOP）升高。

The Company initiated two registrational Phase 3 clinical trials of the BIM-IOL System and continues long-term follow-up of patients in the Phase 1/2 study investigating the safety and efficacy of the BIM-IOL System. SpyGlass Pharma plans to work with the FDA to advance the program through completion of Phase 3 clinical trials, New Drug Application submission, and ultimately to potential FDA approval..

公司启动了BIM-IOL系统的两项注册性III期临床试验，并继续对I/II期研究中的患者进行长期随访，该研究旨在评估BIM-IOL系统的安全性和有效性。SpyGlass Pharma计划与美国食品药品监督管理局（FDA）合作，推动该项目完成III期临床试验、提交新药申请，并最终获得FDA的潜在批准。

About SpyGlass Pharma

关于 SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation..

SpyGlass Pharma 是一家处于后期阶段的生物制药公司，致力于通过对已获批药物进行长效、持续的药物递送，改变慢性眼病患者的治疗范式。公司的使命是通过开发持久的药物递送解决方案，显著提升慢性眼病患者的生活质量，使患者和外科医生能够对长期疾病控制和视力保护充满信心。

The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye..

SpyGlass Pharma平台是一种新型的非生物可降解药物递送技术，旨在与多种成熟且已获批的药物（包括比马前列素和其他小分子药物）联合使用，为潜在治疗眼前段和眼后段的多种疾病提供了灵活性。

The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine..

该公司由马利克·Y·卡胡克（Malik Y. Kahook）医学博士和格伦·苏斯曼（Glenn Sussman）于2019年创立，旨在解决眼科领域缺乏利用持久性治疗方案创新的问题。SpyGlass Pharma平台最初是在科罗拉多大学安舒茨医学院的苏·安舒茨-罗杰斯眼科中心开发的。

Forward-looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding: the potential benefits and impact of the BIM-IOL System on patients; the anticipated benefits of SpyGlass Pharma’s acquisition of AVS, including, without limitation, a scalable commercial IOL capacity, accelerated production of a portfolio of lenses that could fit into the company’s drug delivery pads, and continued support of AVS customers and licensees; and the expectation that SpyGlass Pharma can execute its business plan relating to the AVS acquisition while maintaining its strategy, focus, and existing cash runway.

本新闻稿包含经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条所定义的“前瞻性陈述”。本新闻稿中所有非纯粹历史性的陈述均为前瞻性陈述，包括但不限于以下方面的陈述：BIM-IOL系统对患者的潜在益处和影响；SpyGlass Pharma收购AVS的预期益处，包括但不限于可扩展的商业化人工晶状体（IOL）产能、加速生产可适配公司药物递送垫的一系列镜片产品，以及持续支持AVS的客户和被许可方；以及预期SpyGlass Pharma能够在保持其战略、重点和现有现金续航能力的同时，执行与收购AVS相关的业务计划。

The forward-looking statements contained herein are based upon SpyGlass Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including our ability to manufacture IOLs for the BIM-IOL System, delays in production and an increase in costs, in addition to those set forth in the Risk Factors section of the Company’s Quarterly Report on Form 10-Q for the three month period ended June 30, 2026 filed with the Securities and Exchange Commission on August 6, 2026, and in similar disclosures set forth in the other documents that SpyGlass Pharma has filed and may file from time to time with the SEC.

本文所含的前瞻性陈述基于 SpyGlass Pharma 当前的预期，并涉及可能永远不会实现或可能被证明不正确的假设。这些前瞻性陈述既非承诺也非保证，而是受到各种风险和不确定性的影响，包括我们为 BIM-IOL 系统生产人工晶状体（IOL）的能力、生产延误以及成本增加，此外还包括公司于 2026 年 8 月 6 日向美国证券交易委员会（SEC）提交的截至 2026 年 6 月 30 日的三个月期间 Form 10-Q 季度报告“风险因素”部分中列出的风险，以及 SpyGlass Pharma 已提交或可能不时向 SEC 提交的其他文件中类似披露所列出的风险。

These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise.

这些前瞻性陈述仅截至本新闻稿发布之日，SpyGlass Pharma 不承担更新或修订的义务。

Media Contact:

媒体联系人：

Nami Surendranath

纳米·苏伦德拉纳特

(402) 507-6757

(402) 507-6757

nsurendranath@dnacommunications.com

nsurendranath@dnacommunications.com

Investor Contact:

投资者联系：

Ami Bavishi or Nick Colangelo

阿米·巴维什或尼克·科兰杰洛

Gilmartin Group LLC

吉尔马丁集团有限责任公司

investors@spyglasspharma.com

investors@spyglasspharma.com